Document:

Exhibit
10.6

 

Binding
Side Letter on Exchange Note with Coastal Investment Partners, LLC

dated
July 14, 2017

 

Avant
Diagnostics, Inc. (“AVDX” or the “Company”) hereby proposes the following binding terms (the “Side
Letter”) as agreed with Coastal Investment Partners, LLC (“Coastal”) in connection with the execution of the
Exchange Agreement for settlement of all claims, payments, and damages related to the existing convertible notes (the “2016
Note”) held by Coastal prior to this date:

 

	General:	The
    Company and Coastal (collectively may be referred to herein as the “Parties”) agree that certain obligations of
    the Parties contained in the Exchange Agreement and Convertible Promissory Note shall be deferred.
	 	 
	Deferral:	The
    Parties shall execute the Exchange Note and its ancillary documents as of July 14, 2017, but that the exchange of the 2016
    Note for the Exchange Notes shall be deferred until the Company files the following periodic financial reports with the Securities
    Exchange Commission (the “SEC”):  a) Report on Form 10-Q for the period ended June 30, 2016, December
    31, 2016, March 31, 2017, and June 30, 2017, and b) Report on Form 10-K for the period ended  September 30, 2016
    (the “Outstanding Filings”).  The Company shall have ninety (90) days from the execution of this Side
    Letter to file the Outstanding Filings with the SEC (the “Filing Period”).
	 	 
	Commitment
    Shares:	Per
    the 2016 Note, the Company agrees to issue 750,000 shares of the Company’s common stock to Coastal related to an appropriate
    adjustment due to the Company’s subsequent financing transaction with International Infusion LP and Infusion51a LP in
    November 2016.
	 	 
	Reversion:	If
    the Outstanding Filings are not filed with the SEC prior to the end of the Filing Period the obligations of the Parties under
    the Exchange Agreement and Convertible Promissory Note shall cease and the 2016 Note shall exist with interest accruing from
    the date of this Side Letter
	 	 
	Covenants:	a)
        Should further amendments or modifications occur to this Side Letter, the Exchange Agreement, and/or the Convertible Promissory
        Note, those same amendments and/or modifications will be offered or applied to the Exchange Agreement and Convertible
        Promissory Note held by Infusion 51a, LP, International Infusion, LP, and Infusion related affiliates.

                                                                                      

        b)
        During the Filing Period, Coastal agrees that the Company’s obligations to Coastal under the 2016 Notes, the Exchange
        Agreement, and/or the Convertible Promissory Note are current and not in default in any regard. Coastal agrees to cooperate,
        as necessary, with the Company in its efforts to file its periodic financial reports with the SEC, including communicating
        the status of the Company obligations to Coastal with the Company’s accountants and auditors.

 

AVANT
DIAGNOSTICS, INC

 

By:
_______________________ Date: _____________________

Gerald
E. Commissiong

Director

 

ACCEPTED
AND AGREED:

 

COASTAL
INVESTMENT PARTNERS, LLC

 

By:
_______________________ Date: _____________________Exhibit 10.7

 

EXCHANGE
AGREEMENT

 

This
EXCHANGE AGREEMENT (this “Agreement”) is made effective as of July 28, 2017 (the “Execution Date”)
by and among Avant Diagnostics, Inc., a Nevada corporation (the “Company”) and ____________ (the “Investor”).

 

RECITALS

 

WHEREAS,
the Company and the Investor entered into certain Convertible Promissory Note dated October 28, 2016 (the “Existing Note”),
in the aggregate principal amount of $20,000 and having an initial maturity date of April 28, 2017;

 

WHEREAS,
the Company acknowledges that the Existing Note is currently in default (collectively, the “Default”);

 

WHEREAS,
as a result of the Default, the Company is selling 396,695 common shares of the Company to Investor for $0.00001 per share in
satisfaction of any outstanding accrued and unpaid interest, and penalties, and any other contract obligations in the Existing
Note triggered by the Default (the “Satisfaction Shares”);

 

WHEREAS,
pursuant to a Binding Letter of Intent, executed between the Parties on July 28, 2017 (the “Binding LOI”), the Company
desires, and the Investor agrees, that the Investor exchange (the “Exchange”) the Existing Note for a new convertible
promissory note (the “Exchange Note”), in the form attached hereto as Exhibit A. The Exchange Note shall
have a principal balance of $25,600.00 (twenty five thousand six hundred dollars)(which amount is the $20,000 actual amount of
the purchase price hereof plus a 28% original issue discount), a maturity date of July 28, 2019, accrue interest at a rate of
ten (10%) per annum, a fixed conversion price equal to $0.06 per share, and other terms as provided in this Agreement and the
Exchange Note. The shares of Common Stock in the Exchange Note shall be referred to as the “Conversion Shares”;

 

WHEREAS,
each of the Exchange Note and the Conversion Shares, is intended to qualify as an exempted security under Section 3(a)(9) of the
Securities Act of 1933, as amended (the “Securities Act”).

 

NOW,
THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration
the receipt and adequacy of which are hereby acknowledged, the Company and the Investor agree as follows:

 

ARTICLE
I

THE
EXCHANGE

 

1.1 Waiver of Existing Defaults; Satisfaction Shares. Subject to the terms hereof, Investor hereby irrevocably waive the penalties,
interest, defaults and breaches that have resulted from the Default on or prior to the Execution Date. This waiver does not include
any default occurring after the Execution Date should the Closing not occur. As consideration for this waiver, the Company hereby
sells, transfers, conveys and assigns to the Investor 396,695 common shares at $0.00001, or $3.97 (“Satisfaction Shares”).
Investor shall pay the $3.97 promptly upon execution of this Agreement.

 

1.2 Closing.
Subject to the terms and conditions set forth in this Agreement, the Company and the Investor shall exchange the Existing Note
at the Note Outstanding Balance in consideration for the issuance of the Exchange Note with a total principal balance of $25,600.00.
The closing of the Exchange and issuance of the Convertible Note (the “Closing”) shall take place at the offices
of the Company, on the date hereof or such other date as the parties shall agree (the “Closing Date”).

 

1.3 
Exchange.

 

(a) Escrow.
Effective as of the Execution Date, executed copies of this Agreement and the Binding LOI, the Existing Note and the Exchange
Note, with irrevocable transfer agent instructions, executed by the Company shall be delivered to Austin Legal Group, APC (the
“Escrow Agent”) for possession pursuant to the Binding LOI, and upon successful completion of the conditions
contained in the Binding LOI, the Escrow Agent shall promptly release the Exchange Note to Investor, and the Parties shall agree
that the Existing Note is replaced by the Exchange Note and the Existing Note shall be cancelled and of no further force or effect.
Should the Company not satisfy the conditions contained in the Binding LOI within 120 days from the Effective date of this Agreement,
the exchange of the Existing Note for the Exchange Note shall be cancelled, the Exchange Note shall be of no force or effect and
the Existing Note shall be treated as though it was never cancelled and as having been in default since the Execution Date of
this Agreement.

 

    

     

    

    

(b) Investor
Obligations. At the Closing, the Investor shall deliver or promptly cause to be delivered to the Escrow Agent (i) the Existing
Note, and (ii) an executed copy of this Agreement and (iii) the Binding LOI (as defined below).

 

(c) 
Company Obligations . At the Closing, the Company shall deliver or promptly cause to be delivered to the Escrow Agent and
the Investor (i) the Exchange Note, including properly executed irrevocable transfer agent instructions as detailed in the Exchange
Note, and (ii) an executed copy of this Agreement and Binding LOI.

 

ARTICLE
II

REPRESENTATIONS
AND WARRANTIES

 

2.1 Investor
Representations and Warranties. The Investor hereby represents and warrants to the Company as follows on the
Execution Date and the Closing Date:

 

(a) 
Organization; Authority. The Investor, if not a natural person, is an entity duly organized, validly existing and in good
standing under the laws of the jurisdiction of its organization. The Investor has the requisite power and authority to enter into
and to consummate the transactions contemplated by this Agreement and otherwise to carry out its obligations hereunder. This Agreement
has been duly executed by the Investor, and when delivered by the Investor in accordance with the terms hereof, will constitute
the valid and legally binding obligation of the Investor, enforceable against it in accordance with its terms.

 

(b) 
Ownership of the Existing Note. The Investor is the sole owner of the Existing Note, free and clear of any and all liens,
claims and encumbrances of any kind. The Investor has not assigned any rights in the Existing Notes to any party.

  

(c) 
Investment Intent. The Investor is acquiring the Exchange Note as principal for its own account for investment purposes
only and not with a view to or for distributing or reselling such Exchange Note or any part thereof, except pursuant to sales
that are exempt from the registration requirements of the Securities Act and/or sales registered under the Securities Act. The
Investor does not have any agreement or understanding, directly or indirectly, with any person or entity to distribute the Exchange
Note. Notwithstanding anything in this Section 2.1(c) to the contrary, by making the representations herein, the Investor
does not agree to hold the Exchange Note for any minimum or other specific term and reserves the right to dispose of the Exchange
Note at any time in accordance with or pursuant to a registration statement or an exemption from the registration requirements
under the Securities Act.

 

(d) 
Investor Status. At the time the Investor was offered the Exchange Note, it was, and at the date hereof it is, an “accredited
investor” as defined in Rule 501(a) of Regulation D under the Securities Act. The Investor is not a broker-dealer.

 

(e) 
General Solicitation. The Investor is not acquiring the Exchange Note as a result of or subsequent to any advertisement,
article, notice or other communication regarding the Exchange Note published in any newspaper, magazine or similar media or broadcast
over television or radio or presented at any seminar or any other general solicitation or general advertisement.

 

(f) 
Reliance. The Investor understands and acknowledges that (i) the Exchange Note is being offered and sold to it without
registration under the Securities Act in a transaction that is exempt from the registration provisions of the Securities Act,
and (ii) the availability of such exemption depends in part on, and the Company will rely upon the accuracy and truthfulness
of, the foregoing representations, and the Investor hereby consents to such reliance.

 

(g) 
Brokers and Finders. The Investor has no knowledge of any person who will be entitled to or make a claim for payment of
any finder fee or other compensation as a result of the consummation of the transactions contemplated by this Agreement.

 

    -2-

     

    

 

(h) Experience.
Investor has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating
the merits and risks of the prospective investment in the Exchange Note, and has so evaluated the merits and risks of such investment.
Investor is able to bear the economic risk of an investment in the Exchange Note and, at the present time, is able to afford a
complete loss of such investment..

 

(i) Access
to Information. Such Investor acknowledges that it has had the opportunity to review this Agreement (including all exhibits
and schedules thereto) and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive
answers from, representatives of the Company concerning the terms and conditions of the Exchange Note; (ii) access to information
about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient
to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses
or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to
the investment.

 

2.2 
Company Representations and Warranties. The Company hereby makes the following representations and warranties to each
Investor on the Execution Date and on the Closing Date:

 

(a) 
Organization and Qualification. The Company is a corporation incorporated, validly existing and in good standing under
the laws of the State of Nevada, with the requisite corporate power and authority to own and use its properties and assets and
to carry on its business as currently conducted. The Company is duly qualified as a foreign corporation to do business and is
in good standing in every jurisdiction where the nature of the business it conducts makes such qualification necessary, except
where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result
in: (i) a material adverse effect on the legality, validity or enforceability of the Exchange Note, or this Agreement, (ii) a
material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the
Company, or (iii) a material adverse effect on the Company’s ability to perform in any material respect on a timely basis
its obligations under the Exchange Note, or this Agreement (any of (i), (ii) or (iii), a “ Material Adverse Effect
”).

 

(b) 
Authorization; Enforcement. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and to issue the Exchange Note and the Conversion Shares, upon conversion of the
Convertible Note in accordance with the terms of the Exchange Note, and otherwise to carry out its obligations hereunder and thereunder.
The execution, delivery and performance of this Agreement and any other agreements and the consummation of the transactions contemplated
hereby and thereby have been duly authorized by the Company’s Board of Directors, and no further consent or authorization
of the Company, its Board of Directors (including any committee thereof) or any class of the Company’s stockholders is required.
This Agreement, the Exchange Note have been duly executed by the Company and, when delivered in accordance with the terms hereof,
will constitute the valid and binding obligations of the Company enforceable against the Company, in accordance with their terms,
except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other
laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the
availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.

  

(c) 
Issuance of the Exchange Note. The Exchange Note is duly authorized and, when issued and paid for in accordance with this
Agreement, will be duly and validly issued, fully paid and nonassessable. The Conversion Shares, when issued in accordance with
the terms of the Exchange Note, will be validly issued, fully paid and nonassessable, free and clear of all liens imposed by the
Company other than restrictions on transfer provided for in the Exchange Note or under applicable securities laws.

 

(d) 
No Conflicts. The execution, delivery and performance of this Agreement, and the Exchange Note and the consummation by
the Company of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for
issuance, as applicable, of the Conversion Shares will not, (i) result in a violation of the articles of incorporation of the
Company, as amended (the “Certificate of Incorporation”) or the bylaws of the Company (the “Bylaws”)
or (ii) result in a violation of any law, rule, regulation, order, judgment or decree (including United States federal and state
securities laws and regulations and rules or regulations of any self-regulatory organizations to which either the Company or its
securities are subject) applicable to the Company or by which any property or asset of the Company is bound or affected. The Company
is not in violation of its Certificate of Incorporation, Bylaws or other organizational documents.

 

    -3-

     

    

 

(e) 
Absence of Certain Changes. The Company has not taken any steps, and does not currently expect to take any steps, to seek
protection pursuant to any bankruptcy or receivership law nor does the Company have any knowledge or reason to believe that its
creditors intend to initiate involuntary bankruptcy proceedings with respect to the Company.

 

(f) 
Certain Fees. No fees or commissions will be payable by the Company to any broker, financial advisor or consultant, finder,
placement agent, investment banker, bank or other Person with respect to the transactions contemplated by this Agreement.

 

(g) SEC
Filings. The Company will use its best efforts to become current in all delinquent filings with the SEC, including XBRL data
and posting all required filings and XBRL data on its website, within 120 days from the Effective Date of this Agreement.

 

ARTICLE
III

OTHER
COVENANTS

 

3.1 
Securities Matters. The Investor acknowledges that the Exchange Note, the Satisfaction Shares, and the Conversion Shares,
have not been registered under the Securities Act and may only be disposed of pursuant to an available exemption from or in a
transaction not subject to the registration requirements of the Securities Act. The Company agrees not to interfere with Investor’s
attempts to remove the restrictive legend from or sell any security in the Company so long as done pursuant to a valid opinion
of attorney that such securities are eligible to have the legend removed and/or be sold. To that end, the Company further agrees
after the Company becomes current pursuant to the Binding LOI, it will remain current in all of its required filings with the
SEC and website postings so long as Investor holds any security in the Company and shall not deregister its common shares with
the SEC.

 

3.2 
Restrictive Legend. The Investor agrees to the imprinting of the following legend on the Convertible Note, Satisfaction
Shares, and Conversion Shares, so long as is required under Section 3.1:

 

THESE
SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION, AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OF 1933 AND APPLICABLE STATE SECURITIES LAWS OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR
IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES
LAWS.

 

3.3 Reservation
of Shares. The Company shall at all times have authorized and reserved for the purpose of issuance a sufficient number of
Satisfaction Shares and Conversion Shares.

 

ARTICLE
IV

MISCELLANEOUS

 

4.1 Fees and Expenses. Except as set forth in this Section 4.1, each party shall pay the fees and expenses of its advisers,
counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation, preparation,
execution, delivery and performance of this Agreement. The Company shall pay all stamp and other taxes and duties levied in connection
with the issuance of the Exchange Note.

 

4.2 Entire Agreement; Amendments. This Agreement together with the exhibits and schedules hereto, dated as of the Execution
Date, and the binding letter of intent, dated July 18, 2017 (the “Binding LOI”), collectively, contain the entire
understanding of the parties with respect to the subject matter hereof and supersedes all prior agreements and understandings,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules.

 

    -4-

     

    

 

4.3
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earliest of (i) the date of transmission, if such notice or communication
is delivered via facsimile at the facsimile number or email at the email address specified in this Section prior to 6:00 p.m.
(Eastern time) on a business day, against electronic confirmation thereof, (ii) the business day after the date of transmission,
if such notice or communication is delivered via facsimile at the facsimile number or email at the email address specified in
this Agreement later than 6:00 p.m. (Eastern time) on any date, against electronic confirmation thereof, (iii) the business day
following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) upon actual receipt by the
party to whom such notice is required to be given. The address for such notices and communications shall be as follows:

 

	If
    to the Company: 	Avant
                                         Diagnostics, Inc.

        217
        Perry Parkway

        Suite
        8

        Gaithersburg,
MD 20877

	 	 
	 	Email:

Attn:
Gerald Commissiong, Executive Director

	 	 
	With copies to (which shall not constitute notice): 	Sheppard, Mullin, Richter & Hampton LLP

30 Rockefeller Plaza, 39th Floor

Exchange
York, NY 10112

Facsimile
No.: (917) 438-6137

Email:
scohen@sheppardmullin.com

Attn:
Stephen A. Cohen

 

	If
    to the Investors: 	At
    the address of the Investor set forth on the signature page to this Agreement.

 

or
such other address as may be designated in writing hereafter, in the same manner, by such person or entity.

 

4.4
Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed by the
Company and by the Investor. No waiver of any default with respect to any provision, condition or requirement of this Agreement
shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor
shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right
accruing to it thereafter.

  

4.5
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed
to limit or affect any of the provisions hereof.

 

4.6
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors
and permitted assigns. The Investor may not assign this Agreement or any rights or obligations hereunder without the prior written
consent of the Company.

 

4.7
No Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person or entity.

 

4.8 Governing
Law. This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of
Nevada, without regard to the principles of conflicts of law thereof. The Company and the Investor irrevocably consent to the
jurisdiction of the United States federal courts and state courts located in the State of Nevada in any suit or
proceeding based on or arising under this Agreement and irrevocably agree that all claims in respect of such suit or
proceeding may be determined in such courts.

 

4.9 Survival.
The representations and warranties contained herein shall survive until the expiration of the first anniversary following the
Closing. The agreements and covenants contained herein shall survive the Closing and the delivery of the Exchange Note until
the expiration of the applicable statute of limitations (if any) therefor.

 

    -5-

     

    

 

4.10 Execution. This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that all parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or a scanned copy via electronic mail, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile or
scanned signature page were an original thereof.

 

4.11 Severability.
In case any one or more of the provisions of this Agreement shall be invalid or unenforceable in any respect, the validity
and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affected or
impaired thereby and the parties will attempt to agree upon a valid and enforceable provision which shall be a reasonable
substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Agreement.

 

4.12 Further
Assurances. The parties hereto agree that each shall execute and deliver any and all further agreements,
instruments, certificates and other documents, and shall take any and all action, as any of the parties hereto may reasonably
deem necessary or desirable in order to carry out the intent of the parties to this Agreement.

 

4.13 Attorneys’
Fees. If either party shall commence an action or proceeding to enforce any provisions relating to the obligations to
close the transactions contemplated by this Agreement prior to the Closing, then the prevailing party in such action or
proceeding shall be reimbursed by the other party for its attorneys’ fees and other costs and expenses incurred
with the investigation, preparation and prosecution of such action or proceeding.

 

4.14 Construction.
The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise this Agreement
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party
shall not be employed in the interpretation of this Agreement or any amendments hereto.

 

[signature
page follows]

 

    -6-

     

    

 

IN
WITNESS WHEREOF, the parties hereto have caused this Exchange Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	 	COMPANY: 
	 	 
	 	AVANT
    DIAGNOSTICS, INC.
	 	 	 
	 	By:	                        
	 	Name:	 
	 	Title:	 

 

[additional
signature page follows]

 

[Company
Signature Page to Exchange Agreement]

 

    -7-

     

    

 

INVESTOR:

 

[NAME]

 

	By:	 	 

Name:

Title: 

 

Email
Address of Authorized Signatory: ____________________________

 

Facsimile
Number of Authorized Signatory: ________________________

 

Address
for Notice to Investor:

 

 

[Investor
Signature Page to Exchange Agreement]

 

    -8-

     

    

 

Exhibit
A

 

[Form
of Exchange Note]

 

 

-9-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00275-of-00352.parquet"}]]